- SEK457.99m
- SEK288.67m
- SEK180.16m
Brief: OssDsign: Successful Outcome At 6-Month Follow-Up Of Clinical Study On Sinus Augmentation
Brief: OssDsign Q2 Loss Widens To SEK 22.6 Mln
Brief: OssDsign Signs Business Partner Agreement With Muranaka Medical Instruments
Brief: OssDsign Appoints ABG Sundal Collier As Liquidity Provider
Brief: OssDsign Announces Planned CEO Change
Brief: Ossdsign Q1 Loss After Taxes Widens To sek 18.3 Mln
Brief: OssDsign Cranial PSI Granted Full Nationwide Reimbursement In Japan
Brief: Ossdsign Gets Regulatory Approval And Prepares For Launch In Japan
Brief: OssDsign Q4 Loss After Taxes Widens To SEK 28.6 Mln
Brief: Ossdsign Completes Transfer Of Commercial Operations In The US
Brief: OssDsign Q3 Loss After Taxes Widens To SEK 19.7 Mln
Brief: Karolinska Development's Portfolio Company OssDsign Reports Favourable Outcome Data On OSSDSIGN Cranial PSI
Brief: OssDsign Gets New European Patent
Brief: OssDsign Receives US FDA Clearance For Cranial PSI Accessories
Brief: OssDsign Q2 Loss After Taxes Widens To SEK 18.3 Mln
Brief: OssDsign Initiates Commercial Preparations For Launch In Japan Following Regulatory Filing For OssDsign Cranial
Brief: Ossdsign AB Says Adviser Erik Penser Bank Announces That Stabilization Measures Have Been Undertaken In Co's Shares On Nasdaq First North
Brief: Erik Penser Bank Says Stabilization Measures Have Been Undertaken In Ossdsign's Shares On Nasdaq First North